NECLIFE

Nectar Lifesciences Share Price

 

 

Start SIP in NECLIFE

Start SIP

Performance

  • Low
  • ₹21
  • High
  • ₹21
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹44
  • Open Price₹21
  • Previous Close₹21
  • Volume10,584,128

Investment Returns

  • Over 1 Month + 49.54%
  • Over 3 Month + 43.79%
  • Over 6 Month -13.61%
  • Over 1 Year -36.94%

Smart Investing Starts Here Start SIP with Nectar Lifesciences for Steady Growth!

Invest Now

Nectar Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 470
  • P/B Ratio
  • Average True Range
  • 1.34
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.64
  • RSI
  • 73.09
  • MFI
  • 94.9

Nectar Lifesciences Financials

Nectar Lifesciences Technicals

EMA & SMA

Current Price
₹20.95
+ 0.01 (0.05%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹16.55
  • 50 Day
  • ₹15.66
  • 100 Day
  • ₹16.61
  • 200 Day
  • ₹20.00

Resistance and Support

20.91 Pivot Speed
  • R3 22.02
  • R2 21.64
  • R1 21.29
  • S1 20.56
  • S2 20.18
  • S3 19.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences manufactures and supplies pharmaceuticals, active pharmaceutical ingredients (APIs), and herbal products. With state-of-the-art facilities in India, the company serves global markets, focusing on healthcare, wellness, and life-saving medications for various therapeutic segments.

Nectar Lifesciences has an operating revenue of Rs. 1,171.34 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of -10% needs improvement, ROE of -11% is poor and needs improvement. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 41% and 6% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 6 which is a POOR score indicating inconsistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nectar Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results & Others To consider other business matters.
2025-07-23 Others Inter alia amongst other items, the mode of rewarding of shareholders as contemplated in the explanatory statement to item no. 3 of Notice of 2025-26/01st EGM or matters related thereto.
2025-07-07 Audited Results
2025-01-31 Quarterly Results & Others To consider other business matters.

Nectar Lifesciences F&O

Nectar Lifesciences Shareholding Pattern

44.91%
0%
0.62%
44.7%
9.77%

About Nectar Lifesciences

  • NSE Symbol
  • NECLIFE
  • BSE Symbol
  • 532649
  • Chairman & Managing Director
  • Mr. Sanjiv Goyal
  • ISIN
  • INE023H01027

Similar Stocks to Nectar Lifesciences

Nectar Lifesciences FAQs

Nectar Lifesciences share price is ₹20 As on 08 December, 2025 | 00:59

The Market Cap of Nectar Lifesciences is ₹469.8 Cr As on 08 December, 2025 | 00:59

The P/E ratio of Nectar Lifesciences is -1.3 As on 08 December, 2025 | 00:59

The PB ratio of Nectar Lifesciences is 0.5 As on 08 December, 2025 | 00:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23